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Thesterilealphamotif and leucinezippercontainingkinaseZAK (AZK,MLT,MLK7), is aMAPK-kinasekinase (MKKK). Likemost
MAPKKKswhich are known to activate the c-Jun. amino-terminal kinase (JNK) pathway, ZAKhasbeen shown toparticipate in
the transduction of Transforming growth factor-β (TGF-β)-mediated non-canonical signaling. A role for ZAK in SMAD-
dependent, canonical TGF-β signaling has not been previously appreciated. Using a combination of functional genomics and
biochemical techniques, we demonstrate that ZAK regulates canonical TGFβRI/II signaling in lung and breast cancer cell lines
and may serve as a key node in the regulation of TGFBR kinase activity. Remarkably, we demonstrate that siRNA mediated
depletionof ZAKstrongly inhibitedTGF-βdependentSMAD2/3activationandsubsequentpromoter activation (SMADbinding
element driven luciferase expression; SBE4-Luc). A ZAK specific inhibitor (DHP-2), dose-dependently activated the
bioluminescent TGFBR-kinase activity reporter (BTR), blocked TGF-β induced SMAD2/3 phosphorylation and SBE4-Luc
activation and cancer cell-invasion. In aggregate, these findings identify a novel role for the ZAK kinase in canonical TGF-β
signaling and an invasive cancer cell phenotype thus providing a novel target for TGF-β inhibition.
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Transforming growth factor-β (TGF-β) is an evolutionarily conserved
superfamily of cytokines that regulate many cellular functions in a
context dependent manner. TGF-β signals through a heteromeric
receptor complex consisting of type I (TGFBR1) and type II
(TGFBR2) serine/threonine kinase receptors. TGF-β binding to
TGFBR2 leads to its phosphorylation and subsequent recruitment
and activation of TGFBR1. Activated receptor complex subsequently
recruits and phosphorylates receptor regulated smads (R-Smads).
R-smads (SMAD2/3) form a complex with a co-smad (SMAD4) and
translocate to nucleus where they regulate transcriptional responses.
TGF-β also activates other signaling cascades, including MAPK
pathways. Ligand-dependent activation of the TGF-β receptors and
regulation of their subsequent kinase activity is a complex process
involving multiple positive and negative regulatory mechanism [1,2].
ZAKwas identified in a human kinome siRNA screen utilizing a live cell
reporter for TGFBR1 kinase activity (BTR; [3,4]).
The sterile alpha motif and leucine zipper containing kinase ZAK
(AZK, MLT, MLK7) is a MAP kinase kinase kinase. These mixed
lineage kinases (MLKs) cluster into three subgroups based on thedomain arrangements and sequence similarity within their catalytic
domains: the MLKs, the dual-leucine-zipper-bearing kinases, and
zipper sterile-α-motif kinase (ZAK). ZAK is an 800 amino acids protein
that contains a kinase catalytic domain, a leucine zipper, and a
sterile-a-motif (SAM). ZAK has two isoforms, the larger one (ZAK-α or
MLK-like MAP triple kinase-α; MLTK-α) and an alternative splicing
product (ZAK-β, MLTK-β or MLK7) which lacks a SAM domain
474 Regulation of canonical TGF-β signaling by ZAK Nyati et al. Translational Oncology Vol. 9, No. 6, 2016[5,6]. Similar to other MLK family members, the MLTKs regulate
signaling of the extracellular signal-regulated kinase (ERK), c-Jun,
N-terminal kinase (JNK), and p38 kinase.
ZAK expression in mammalian cells has been shown to regulate
JNK/SAPK pathway and NF-κB transcription factor activation [7].
MLTK-α overexpression has been shown to enhance anchorage
independent growth in response to EGF [8]. ZAK has been shown to
inhibit growth of lung cancer cells via ERK and JNK activation in an
AP-1 dependent manner [9]. ZAK has also been shown to be a critical
component of TGF-β dependent hypertrophic growth in cardiomyo-
blast cells [10]. Over-expression of a dominant-negative mutant of
ZAK was shown to abolish TGF-β induced features of cardiac
hypertrophy, including increased cell size, higher expression of atrial
natriuretic factor (ANF) and increased organization of actin fibers
[10]. Although these data implicate ZAK in non-canonical TGF-β
signaling, its role in canonical TGF-β signaling in cancer is unclear.
We herein describe a role for ZAK in TGF-β mediated canonical
(SMAD2/3) signaling. siRNA mediated depletion of ZAK or its inhibition
using DHP-2 resulted in activation of a reporter for the TGFBR1 kinase
activity, attenuated SMAD2/3 activation as well as downstream transcrip-
tional activity (SBE4-Luc), and an invasive cellular phenotype. We further
show that the interaction of ZAK to TGFBR1 is independent of ligand
mediated activation as well as SB-431542 mediated inhibition of TGFBR1
kinase activity. Taken together, our data show that ZAK kinase activity plays
an important role in canonical TGF-β signaling thus providing an additional
node for the regulation of this key oncogenic pathway.
Materials and Methods
Plasmid DNA
BTR WT reporter has been described earlier [3]. SBE4-Luc [11]
reporter plasmid was provided by Dr. Bert Vogelstein (Addgene
plasmid #16,527). pCMV5-TGFBRI-His (#19,161) was provided by
Dr. JoanMassague [12]. ZAK cDNA clone was obtained fromHarvard
DNA repository and cloned into pEF vector backbone expressing
3XFL-tag. ZAK dominant negative (ZAK-dn; Lys45Met [13]) and
constitutively active ZAK (ZAK-EE; Ser230/234Glu [13]) were created
by site directed mutagenesis.
Antibodies and Reagents
Antibodies to pSMAD2, SMAD2, pSMAD3, TGFΒR1, c-JUN,
pERK1/2 ERK1/2 and GAPDH (all from Cell Signaling), SMAD3
(Invitrogen), TGFBR1 (V22), and SARA (Santa Cruz biotechnology),
firefly luciferase (Millipore), Flag-HRP (Sigma), His-tag-HRP (clone
H3; Invitrogen), and His-tag (clone H8; Millipore), ZAK monoclonal
antibodyMO3 (clone 3G5; Abnova) and ZAK polyclonal antibody was
from Novus Biologicals. The HRP-conjugated secondary antibodies
were from Jackson ImmunoResearch. Recombinant human TGF-β1
was obtained from HumanZyme, Alkaline phosphatase was purchased
from New England Biolabs (NEB). TGFΒR1 inhibitors SB-431,542
and SD-208 were obtained from Cayman Chemical and D-Luciferin
from Xenogen Corp. ZAK siGENOME Smart Pool siRNA as well as
non-silencing siRNA (NSS) were obtained from GE-Dharmacon. The
small molecular weight inhibitor of ZAK (DHP-2) was provided by
Laura J Bloem from Eli Lilly [14].
Cell Culture and Transfection
The human lung carcinoma cell line A549 and normal kidney cell
line HEK293T were obtained from American Type Culture
collection (ATCC) maintained in RPMI-1620 or DMEM mediarespectively supplemented with 10% heat-inactivated fetal bovine
serum, 1% glutamine, and 0.1% penicillin/streptomycin/gentamycin
(GIBCO-Invitrogen). Cells were grown in a humidified incubator at
37 °C and 5% CO2. Breast cancer cell line 1833 [15] derived from
MDA-MB-231 was kindly provided by Dr. Joan Massague (Memorial
Sloan Kettering Institute, NY) and maintained in DMEMmedia in the
same conditionsmentioned above. A549 andMDA-231-1833 cell lines
stably expressing the BTR reporter were previously generated [3] and
maintained as described. siGENOME siRNA pool were transfected
using Dharmafect1 while plasmids were transfected using Fugene6.Western Blot Analysis
Western analysis was carried out using standard protocols. Cells
were grown in culture dishes, transfected with specific siRNA or
plasmids, or treated with select compounds and TGF-β for designated
time periods, and cell lysates were resolved on SDS-PAGE gels and
transferred to PVDF membranes. Membranes were probed against
specific primary antibodies followed by HRP conjugated secondary
antibodies then visualized using the Enhanced Chemiluminescence
(ECL) Western Blotting System (GE Healthcare). Signal intensity
was measured using an image processing and analysis program
(ImageJ, v1.45) [16].
Co-Immunoprecipitation
For co-immunoprecipitation studies HEK293T cells were trans-
fected with the indicated plasmids in 10 cm plates. Cells were treated
with TGF-β and inhibitors for the indicated time and lysates were
made 48–72 h post-transfection in IP-lysis buffer (50 mM Tris PH
7.4, 1% NP40, 0.25% Deoxycholate sodium salt, 150 mM NaCl,
10% Glycerol, and 1 mM EDTA) supplemented with 1X PhosStop
(Roche), 1X Protease inhibitor cocktail (Roche), Sodium Ortho
Vanadate, Sodium fluoride, PMSF, and β-Glycerol phosphate (2 μM
each). Protein estimation was performed using detergent compatible
Dc assay kit (Pierce). Lysates were pre-cleared by incubating with
normal Rabbit-IgG for 1 h followed by 30 μl protein A/G-coupled
Sepharose beads (GE Healthcare) for an additional hour at 4 °C and
centrifuged. Co-immunoprecipitation was carried out by incubating
pre cleared cell lysate (400 μg protein) with 1.5 μg TGFBR1 or ZAK
specific polyclonal antibodies overnight at 4°C. The immune complex
was captured using 30 μl slurry of protein A/G-coupled Sepharose
beads for 2 h, washed four times with lysis buffer. For the Flag-tag IP,
lysates were pre-cleared with normal mouse IgG- and protein A/
G-coupled Sepharose beads and the immunoprecipitation was carried
out using Flag-M2 beads (Sigma) for 2 hours at room temperature.
The resulting pellet was resolved by SDS-PAGE and transferred to
PVDF membrane for western-analysis.
BTR Reporter Assay
A549-BTR (5×103 cells/well) and MDA-231-1833-BTR (6×103
or cells/well) cell lines were seeded in 96-well black-walled,
clear-bottom plates (Corning, Inc., Corning, NY) 24 to 48 hours
prior to assaying. Cells were treated in serum-free media with various
concentrations of DHP-2 or SD-208 for indicated time periods.
Saturating concentration of the firefly luciferase D-Luciferin (100 μg/ml
final concentration)were added to themedia 5minutes before starting the
live-cell luminescence imaging. Photon counts for each condition were
acquired for 60 seconds at medium binning using an IVIS 200 imaging
system (Xenogen-PerkinElmer, Alameda, CA) for 15 sequences for each
time point.
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Figure 1. ZAK mediates TGF-β dependent SMAD2 phosphorylation.
The Bioluminescent TGF-β reporter expressing lung (A549-BTR;
A) and breast (1833-BTR; B) cancer cell lines were transfected
nonspecific scrambled control (NSS, negative control) or ZAK
specific siRNA and bioluminescence was measured 72 hours post
transfection. Bar graphs are mean of at least three biological
replicates. Error bars represent ±SD. In parallel experiments, A549
and MDA-231-1833 cells were transfected with control or ZAK
specific siRNA, serumstarved, treatedwith 5 ng/mLTGF-β for 1 hour.
Extracts were prepared and analyzed for phosphorylated SMAD2
and SMAD2 abundance by immunoblot analysis (C). ZAK immuno-
blotting was performed to confirm the knockdown efficiency.
Western-blot quantitation was performed using Image J. Bar graphs
aremean absorbance units (AU) of at least three biological replicates
(TGF-β treated samples only). Error bars represent ±SD. Relative
firefly luciferase activity (normalized to Gaussia luciferase) in
MDA-231-1833 (D) cells transiently transfected with the SBE4-Luc
reporter plasmid and aGLuc plasmid and treatedwith 10 ng/mL TGF-β
for 24 hours. Data are means ± S.E.M. of 3 biological replicates. Total
cellular extractswereprepared in parallel experiments andprobedwith
luciferase and ZAK specific antibodies to confirm the transfection
efficiency and treatment (E). GAPDH was used as a loading control.
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For SBE4-Luc reporter studies, 1.25 X 105 MDA-231-1833 cells
were plated in 12 well plates 1 day prior to transfection. Cells were
transfected next day with 100 ng SBE4-Luc plasmid, 100 nM siRNA,
and 20 ng Gaussia-Luciferase (internal control for transfection
efficiency) for each well with Lipofectamine 2000. Cells were serum
starved 24 h post transfection for 6 h and treatedwith 10 ng/mLTGF-β
for 24 h before measuring SBE4-Luc bioluminescence activity.
Alternately, cells were treated with 10 μM SB-431,542 or DHP-2 in
the presence of TGF-β. Cells were washed twice with PBS and kept in
fresh media for 8-24 h before measuring Gaussia-Luc activity.
Hanging Drop Cell Invasion Assay
The invasive nature of cancer cell lines as a correlate of metastatic
potential in a biologically relevant three dimensional format was
evaluated using the cell spheroid invasion assay [17]. Gravity was used
to generate spheroids within drops of media that hang from the lid of
a cell culture dish. Next, these spheroids are embedded in a 3D matrix
consisting of a mixture of basement membrane materials and type I
collagen. Cancer cell egression from the spheroids into the
surrounding matrix was then monitored over time.
Results
ZAK Regulates Canonical TGF-β Signaling
In an effort to identify novel regulators of TGF-β dependent
Smad activation, we utilized a protein complementation reporter for
SMAD2 targeted TGFβR1 kinase activity (BTR) [3].
TGF-β-responsive lung adenocarcinoma cells (A549) as well as a
metastatic variant breast cancer cell line (MDA-231-1833, [18]) were
engineered to stably express the reporter and utilized in a
high-throughput siRNA screen against the Human Kinome library.
This screen led to the identification of ZAK among several other
kinases as regulators of canonical TGF-β signaling [4]. Although a
role of ZAK in non-canonical TGF-β signaling (MAPK) and its
interaction with TGFBR1 have been described [10], a role for ZAK in
canonical (SMAD2/3 dependent) TGF-β signaling has not been
previously appreciated. Studies wherein siRNAmediated knock down
of ZAK in BTR expressing cells resulted in an increase in the BTR
activity compared to non-targeted scrambled siRNA (NSS) cells
validated the screen (Figure 1, A and B). Biochemical confirmation
was accomplished by ZAK specific siRNA knockdown followed by an
over-night serum starvation and treatment with TGF-β for 1 hour.
Analysis of SMAD2-phosphorylation from the resulting cell extracts
revealed a decrease in phospho-SMAD2 levels when ZAK expression
was knocked out, whereas no change in the level of total SMAD2 was
observed (Figure 1C). Similarly SMAD3 phosphorylation was also
reduced in ZAK knockdown cells (Supplementary Figure 1A). This
data indicates that ZAK is required for TGF-β mediated SMAD2/3
activation (canonical TGF-β signaling).
SMAD2/3 phosphorylation in response to TGF-β leads to their
translocation to the nucleus, leading to transcriptional activation of
target genes [19]. To investigate if TGF-β dependent transcriptional
regulation is also affected by ZAK, MDA-231-1833 cells were
transfected with a Smad-binding element driven luciferase reporter
plasmid (SBE4-Luc [20],) in the presence or absence of ZAK
knockdown. Overnight stimulation of cells using TGF-β, resulted in
an increase in SBE4-Luc activity in NSS transfected cells, whereas
cells wherein ZAK was knocked down had a diminished response to
TGF-β stimulation (Figure 1D). Immunoblot analysis of the lysatesrevealed a decrease in SBE4-Luc derived luciferase expression in the
presence of ZAK knockdown (Figure 1E) compared to control
siRNA-transfected cells, further confirming results obtained from
luciferase activity assays.
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476 Regulation of canonical TGF-β signaling by ZAK Nyati et al. Translational Oncology Vol. 9, No. 6, 2016Based on the mRNA expression data (Oncomine.org) ZAK is in
the top 10% of over-expressed genes in colorectal, gastric, head &
neck cancers and in lymphoma, while it is under-expressed in breast,
bladder and lung cancers (representative data in Supplementary
Figure 1, B and C). Furthermore, to investigate whether overexpres-
sion of ZAK had any effect on autocrine TGF-β signaling or
downstream effector molecules, we overexpressed wild type (WT,
kinase active), dominant negative (kinase inactive, dn, [13]) as well as
a constitutively active (ZAK-EE) mutant of ZAK in HEK293T cells
(Supplementary Figure 1D). Transfected cells were serum starved and
treated with TGF-β in the presence or absence of SB431542.Resulting lysates were resolved on SDS-PAGE gels. In contrast to
empty vector transfected cells, over expression of ZAK-WT did not
potentiate TGF-β response as observed by similar activation of
SMAD2. However, over expression of WT and constitutive active
ZAK led to markedly increased activation of a TGF-β responsive gene
c-Jun. as well as ERK1/2 (Supplementary Figure 1D).
ZAK Interacts With TGFBR1 in a Ligand Independent Manner
To provide biochemical support for the above findings, we
investigated if ZAK interacted with TGFBR1 and whether this
interaction was dependent on TGFBR1 kinase activity. HEK293T
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Histidine-tagged TGFBR1 (His-TGFBR1). Stimulation of trans-
fected cells with TGF-β for 48 hours followed by immunoprecip-
itation of the resulting lysates using antibodies against Flag-tag, ZAK
or TGFBR1, revealed similar interaction of ZAK to TGFBR1 in
response to TGF-β treatment (Figure 2A). Furthermore, parallel
studies wherein cells were treated with SB-431,542 revealed that
inhibition of TGF-β-receptor kinase activity did not significantly
impact the interaction of ZAK with TGFBR1 (Figure 2B).
Based on the above finding that ZAK was required for TGF-β
dependent SMAD2 phosphorylation, we investigated if ZAK
interacts with SARA and SMAD2/3, key components of the
canonical cascade. HEK293T cells were transfected with
FL-SMAD2 or FL-SMAD3 as well as HN-ZAK, overnight starved
cells were then treated with TGF-β ligand for 1 hour and lysates were
prepared for immunoprecipitation using antibodies against Flag-tag
or SARA. The resulting pellets were probed with a ZAK specific
antibody as well as Flag-tag, SMAD2 or SARA specific antibodies. No
interaction of ZAK with SMAD2/3 or SARA was detected (Figure 3),
although as a positive control interaction of SMAD2 with SARA was
readily detected (Figure 3).
ZAK Inhibitor DHP-2 Blocks Canonical TGF-β Signaling
DHP-2 (7-[3-fluoro-4-aminophenyl-(4-(2-pyridin-2-yl-5,6-
dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl))]-quinoline), an inhibitorof ZAK [14,21,22] was utilized to further delineate the role of
ZAK-kinase activity in canonical TGF-β signaling. A549 or
MDA-231-1833 cells expressing the BTR reporter were treated
with TGF-β in the presence of various concentrations of DHP-2 and
imaged for BTR activity. Inhibition of ZAK kinase activity resulted in
a dose dependent increase in bioluminescence (Figures 4, A and B
and 5, A and B) indicative of inhibition of canonical TGF-β
signaling. Parallel experiments revealed that the IC50 for DHP-2
mediated BTR activation was 1.66 μM and 1.56 μM for A549 and
MDA-231-1833 respectively (Figures 4C and 5C). The efficacy ofDHP-2
was similar to SD-208, a TGFBR-inhibitor (Figures 4C and 5C).
To confirm that inhibition of ZAK kinase activity using DHP-2
resulted in abrogation of TGF-β signaling, A549 cells were treated
with various concentrations of DHP-2 in the presence of TGF-β for 1
hr. The resulting lysates were probed using a phospho-SMAD2 as
well as a phospho-SMAD3 specific antibody (Figure 5D). A robust
decrease in TGF-β stimulation mediated phosphorylation of SMAD2
as well as SMAD3 was observed in the presence of DHP-2 at
sub-micromolar concentrations (Figure 5D). There was no apparent
change in the levels of total SMAD2/3, TGFBR1, ZAK or luciferase
(reporter). Since ZAK is a MAP kinase kinase kinase and is known to
play a role in ERK1/2 activation, we additionally carried out western
blotting using pP38MAPK and pERK1/2 antibodies to demonstrate
that DHP2 at the used concentrations efficiently inhibited ZAK
kinase activity (Figure 5D).
To further confirm a role for ZAK kinase activity in TGF-β
dependent canonical signaling and its resulting transcriptional
response, we utilized the SBE4-Luc assay. MDA-231-1833 cells
were transfected with the SBE4-Luc plasmid and stimulated with
TGF-β in the presence or absence of DHP-2 as well as the TGFBR1
inhibitor (positive control, SB-431542) (Figure 4D). In agreement
with the decrease in SMAD2/3 phosphorylation observed above,
DHP-2 also inhibited the Smad-dependent transcriptional response
with an efficacy similar to SB-431542 at 10 μM.
Since the transcriptional response to TGF-β leads to enhanced
cancer cell migration and invasion, we investigated if ZAK kinase
activity played a role in these cellular phenotypes. MDA-231-1833
cells were allowed to form hanging drop colonies in soft agar [23] and
treated with TGF-β alone or TGF-β in the presence of various
concentrations of SB-431542 or DHP-2 and allowed to invade for 96
hours (Figure 6, A and B). As shown in Figure 6A, TGF-β
stimulation resulted in enhanced cell migration which was signifi-
cantly inhibited in the presence of DHP-2. In contrast, SB-431542
seemed to reduce the migration of large groups of cells, the migration
of single cells was not completely inhibited even at the maximum
concentration tested (10 μM; Figure 6B).
DHP-2 Inhibits Dimerization of ZAK
Overexpression of ZAK results in distinct higher molecular weight
bands which have been shown to be due to its autophosphorylation
[10,24] and dimerization [13]. We overexpressed wild type (WT,
kinase active) as well as a dominant negative (kinase inactive, dn,
(13)) mutant of ZAK in HEK293T cells. Transfected cells were
serum starved and treated with TGF-β in the presence or absence of
DHP-2 or SD-208 (Figure 7). Resulting lysates were either treated
with alkaline phosphatase or left untreated and resolved on
SDS-PAGE gels (Figure 7). In contrast to wild-type ZAK
(ZAK-WT), cells overexpressing the catalytically inactive, dominant
negative mutant of ZAK (ZAK-dn) lacked higher molecular weight
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These higher molecular weight bands were also reduced upon alkaline
phosphatase treatment of cell lysates, indicating a role for
phosphorylation in their slower migration. Treatment with DHP-2
also resulted in a decrease in these higher molecular weight bands,
which could not be further reduced by alkaline phosphatase (Figure
7). In contrast, SD-208 treatment did not significantly impact the
levels of these higher molecular weight bands indicating that a TGF-β
inhibitor did not significantly alter ZAK kinase activity.
Discussion
Although a role for ZAK in non-canonical TGF-β signaling and
hypertrophic growth of cardiomyoblasts through MAPK signaling has
been described [10], its role in cancer and TGF-βmediated canonicalsignaling has not been appreciated. Identification of ZAK in our
siRNA screen [4] using a reporter for SMAD-targeted kinase activity
(BTR; [3]) was unexpected and prompted us to study this further.
Biochemical studies of the results obtained using the BTR screen
confirmed a role for ZAK in TGF-β dependent SMAD2/3
phosphorylation, target gene expression and an invasive cellular
phenotype. Since ZAK is a Ser/Thr kinase, we investigated a role for
its kinase activity in TGF-β mediated SMAD2/3 signaling using
DHP-2, a specific small molecule inhibitor [14]. DHP-2 treatment of
BTR expressing A549 lung cancer and MDA-231-1833 breast cancer
cells not only activated the BTR reporter in a dose and time
dependent manner, but also inhibited SMAD2/3 phosphorylation,
target gene expression (SBE4-Luc reporter) and also inhibited cellular
phenotypes such as tumor cell invasion. Our finding that DHP-2
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Figure 5. ZAK inhibitor blocks TGF-β signaling in A549 cells. (A) A549-BTR cells were treated with various concentrations of DHP-2 (0, 0.1,
0.5, 1, 5 and 10 μM) and the BTR reporter response wasmeasured serially up to 6 hours. The increase in the bioluminescence activity over
DMSO treatment (0 μM) levels was calculated and plotted as fold induction. Bioluminescent measurements are in triplicates, error bars
denote SEM. (B) A549-BTR reporter activation in response to DHP-2 concentrations at 30 minutes is plotted to illustrate dose-dependent
increase in the reporter activity. Data points represent the mean ± SEM for each condition. Pearson correlation coefficient (r), goodness
of fit (R2) and statistical significance (P b .05 *; P b .001**) is calculated and shown on the plot. (C) A549-BTR cells were treated with ZAK
kinase inhibitor (DHP-2) to estimate the IC50 values in live cells under physiological conditions. Three independent experiments were
performed with 8 replicates for each dose. TGF-β signaling inhibitor SD-208 was used as a positive control for the assay. (D) A549-BTR
cells were treated with increasing concentrations of DHP-2 (0, 0.1, 0.5, 1, 5 and 10 μM) in presence of TGF-β (10 ng/mL) for 1 hour and
resulting lysates were probed with the antibodies indicated. The dividing vertical line in pSMAD3 blot indicate the splice junction.
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micromolar concentrations in live cells is consistent with previous
results that inhibition of ZAK was also effective at preventing the
activation of TGF-β mediated p38MAPK and JNKs in COS-7 and
HCT-8 cells [14,21,22] at similar concentrations. Furthermore, as
previously reported [10], ZAK was shown to interact with TGFBR1,
although inhibition of TGFBR1 kinase activity using SB-431542 in
the presence of ligand did not have a significant impact on the
interaction of ZAK with TGFBR1 suggesting that ZAK is
constitutively bound to the TGFBR1 irrespective of the activation
status. A small but reproducible enhancement of the interaction in
response to TGFBR1 inhibition was observed. This could be
explained by the fact that inhibition of TGFBR1 would lead to
decreased internalization and degradation of TGFBR1-TGFBR2
complex [25] and thus leading to the appearance of an enhanced
interaction with ZAK.We also evaluated the possibility that ZAK may interact with
SMAD2/3 or SARA. Although as expected, an interaction between
SARA and Smad2 was detected in the presence of ligand, an
interaction between ZAK and SARA or SMAD2/3 was not detected.
In aggregate, although these findings demonstrate a requirement for
ZAK and its kinase activity in TGF-β mediated Smad signaling,
ligand dependent recruitment of ZAK to the activated receptor or
associated accessory proteins was not observed. It is possible that ZAK
may interact with TGFBR2 and that this interaction may be
conditional on activation, although this possibility was not
investigated in our current study.
Although the target substrate of ZAK kinase activity in canonical
TGF-β signaling is not yet known, autocatalytic hyperphosphoryla-
tion has been demonstrated [10,24], therefore, we evaluated
autophosphorylation of ZAK in presence or absence of TGF-β
stimulation. Our findings demonstrate that ZAK indeed is
AB
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Figure 6. ZAK inhibitor DHP-2 blocks TGF-β mediated cell invasion. MDA-231-1833 cells were plated in hanging drop culture in collagen
and allowed to solidify. Media with TGF-β alone (5 ng/mL) or in presence of increasing concentrations of DHP-2 (A) or SB-431542 (B) was
added and cells were allowed to invade for 96 hours. Light micrographs were captured and the cell invasion was analyzed by ImageJ.
480 Regulation of canonical TGF-β signaling by ZAK Nyati et al. Translational Oncology Vol. 9, No. 6, 2016autophosphorylated since the hyperphosphorylated forms of the
protein were not detected when the catalytically inactive mutant
(ZAK-dn) was expressed in HEK293T cells. In agreement with the
above finding, inhibition of TGF-β signaling using SB-431542 did
not reduce hyperphosphorylation of ZAK. A decrease in the
slower-migrating (hyperphosphorylated) form of ZAK in the presence
of alkaline phosphatase confirmed that this form was due to
autophosphorylation. In agreement, the observation that the
expression of ZAK-dn did not yield the hyperphosphorylated
forms, and in addition treatment with the ZAK inhibitor DHP-2
but not SD-208 (TGFBR1 inhibitor) also resulted in a decrease in the
level of the hyperphosphorylated form of the protein, further
confirming that the hyperphosphorylation was autocatalytic.
The importance of ZAK and its isoforms in gastric cancer has been
emphasized by a recent study [26] wherein more than 50 alternativelyspliced forms were shown to be expressed in cancer. The TV1
(ZAK-α) isoform was found to be preferentially up-regulated in
gastric, colorectal, bladder and breast cancers tumors and tumor cell
lines. Overexpression of the TV1 isoform led to the activation of
oncogenic pathways, while siRNA mediated depletion of ZAK in
gastric cancer cell lines inhibited their proliferation [26].
Over-expression of ZAK has also been shown to lead to neoplastic
cell transformation and tumorigenesis in athymic nude mice [8]. Cell
proliferation and neoplastic transformation was abrogated by shRNA
mediated depletion of ZAK in epithelial cells [8].
Sorafenib, a multi kinase inhibitor (including C-Raf, B-Raf and
VEGF) approved for the treatment of kidney and liver cancers also
inhibits ZAK at an IC50 of 48.6 nM [27]. Adverse events of
Sorafenib in patients undergoing chemotherapy have been ascribed to
the ZAK targeted activity of the agent. Although DHP-2 also inhibits
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Figure 7. DHP-2 is a ZAK specific inhibitor. (A) HEK293T cells were
transfected with plasmids expressing kinase active ZAK (ZAK-WT),
ZAK dominant negative (ZAK-dn) or constitutively active ZAK
(ZAK-EE), serum starved over-night and treated with TGF-β (10
ng/mL) alone or in presence of SB-431,542 (10 μM) for 1 hour.
Resulting lysates were probed with antibodies against ZAK, c-Jun.,
pERK1/2 and total ERK1/2. (B) HEK293T cells were transfected with
ZAK-WT or ZAK-dn, serum starved over-night and treated with
TGF-β (10 ng/mL) alone or in presence of SD-208 (10 μM) or DHP-2
(10 μM) for 1 hour. Resulting lysates were incubated with alkaline
phosphatase for 1 hour or left untreated and resolved on
SDS-PAGE gels and probed with antibodies against ZAK, Flag-tag
or GAPDH. The dividing vertical lines in western blots indicate the
splice junction.
Translational Oncology Vol. 9, No. 6, 2016 Regulation of canonical TGF-β signaling by ZAK Nyati et al. 481ZAK at nanomolar concentrations, little information is available on
the specificity of DHP-2 on kinases other than ZAKβ, MLK2 and
JNK. Our observation that DHP-2 inhibits TGF-β mediated cell
migration in MDA-231-1833 cells emphasizes a role for ZAK in
TGF-β mediated canonical signaling.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.09.010.
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